QS-7 Fraction Adjuvant(A Superior Adjuvant for Cutting-Edge Vaccine Development)

Product Overview

QS-7group is a highly purified water-soluble triterpene saponin derived from the bark of the Quillaja saponaria (South American soapbark) tree. QS-7 group is established as the adjuvant in two approved human recombinant protein vaccines, renowned for its synergistic effect with QS-21 to induce robust and well-balanced immune responses. Currently, dozens of vaccine candidates incorporating QS-7 group are in active clinical development.

However, as a natural product, QS-7 group faces significant challenges, including limited geographic sourcing and inherent variability in quality stability. GC Biotech addresses these challenges through rigorous raw material sourcing, multi-tiered quality control, and advanced purification processes, ensuring consistent supply of pharmacopoeia-compliant QS-7 group to meet the R&D and production needs of both domestic and global markets.

Mechanism of Action

QS-7group is a potent immunomodulator that enhances vaccine efficacy through multiple mechanisms:

• Cross-Activation of Immune Pathways: Targets critical antigen-presenting cells (APCs) and T-cell populations, enabling synergistic activation of both humoral (antibody-mediated) and cell-mediated immunity.

• Antigen Presentation Efficiency: As a semi-hydrophilic surfactant, QS-7 enhances antigen uptake, processing, and MHC-mediated cross-presentation in APCs, maximizing immune system recognition.

• Direct T-Cell Stimulation: Activates T cells via CD2 receptor engagement, triggering Th1-associated cytokine secretion and skewing the immune response toward a Th1 profile, ideal for cellular immunity.

These mechanisms collectively amplify the vaccine’s ability to generate protective immunity against pathogens and diseases.

Applications

QS-7group demonstrates exceptional versatility across a wide spectrum of vaccine types:

Therapeutic Vaccines

• Oncology: Melanoma, brain tumors, breast, uterine, and lung cancers.

• Neurodegenerative Diseases: Mechanisms not yet fully elucidated but show promise.

• Infectious Diseases: Broad antigen compatibility.

Formulation Flexibility

QS-7group can be integrated into vaccines via various strategies:

1. Liposome, nanoparticle or Bisphospholipid Complexes: Enhances delivery and targeting.

2. Surface Activity Neutralization: Improves tolerability in sensitive formulations.

3. Alkaline Stability: Maintains adjuvant potency in extreme pH environments.

Suggested Preclinical Dosages

• Mouse: 10–20 μg

• Guinea Pig: 25–50 μg

• Rabbit/Monkey: 50–100 μg

Product Specifications

Why Choose GC Biotech’s QS-7?

• Unmatched Quality: Stringent quality control ensures batch-to-batch consistency and compliance with international pharmacopoeial standards.

• Global Compatibility: Performance validated in both preclinical and clinical studies for diverse antigen types.

• Customizable Solutions: Tailored formulations to meet specific vaccine development requirements.

• Reliable Supply: Secured sourcing and scalable production to support large-scale manufacturing.

Contact us to integrate QS-7 group into your next vaccine project or to discuss custom formulation strategies.

Note: For detailed product documentation, including structural diagrams or stability studies, please inquire.

This version adopts a professional tone, concise formatting, and actionable language optimized for Western technical audiences, emphasizing scientific rigor, regulatory compliance, and practical utility.